We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood and Body Fluid Analyzer Developed for Medium-Sized Labs

By LabMedica International staff writers
Posted on 21 May 2009
A new, automatic analyzer has been developed for analysis of blood and body fluids in hospitals with medium-sized laboratories. More...
The analyzer will play an important part in the diagnosis of a number of diseases, including different types of infection and leukemia.

Automated digital cell morphology is the process by which cells are automatically located on a stained peripheral blood or body fluid smear, preclassified, stored, and presented for confirmation by a technologist. The images then become available for access by physicians at any time for perusal.

Using the new analyzer laboratories can achieve time reductions (up to 50 %) and more standardized analyses. To count and classify white blood cells is a very common routine analysis in hematology laboratories. Trends indicate that medium-sized laboratories would like to automate the analytical process. Increased automation gives lab personnel more time and increases objectivity, safety, and standardization in the analytical work.

Called CellaVision DM1200, the instrument is CellaVision's (Lund, Sweden) next generation analyzer, and is the latest addition to the company's current range of products that include CellaVision DM96 and CellaVision DM8. The new instrument is based on a new cost-reduced hardware platform, is automated, and has a wider range of uses. Body fluid software can be added to the analyzer for analysis of fluids such as cerebrospinal fluid.

The official product launch will take place at the international Annual Meeting & Clinical Lab Expo AACC in Chicago, USA, on July 20-24, 2009. CellaVision DM1200 will be commercially available in Europe in around the same time.

CellaVision AB develops and markets systems for automatic differentials of white blood cells and erythrocyte morphology, and software for education and quality assurance of differentials.

Related Links:

CellaVision



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Thyroid Test
Anti-Thyroid EIA Test
New
Automated Coagulation Analyzer
Hemolumi H6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.